Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
RNA Biol. Author manuscript; available in PMC 2010 September 29.
Published in final edited form as:
RNA Biol. 2006 Jan–Mar; 3(1): 1–9.
Published online 2006 January 12.
PMCID: PMC2947206

A-to-I RNA Editing and Human Disease


The post-transcriptional modification of mammalian transcripts by A-to-I RNA editing has been recognized as an important mechanism for the generation of molecular diversity and also regulates protein function through recoding of genomic information. As the molecular players of editing are characterized and an increasing number of genes become identified that are subject to A-to-I modification, the potential impact of editing on the etiology or progression of human diseases is realized. Here we review the recent knowledge on where disturbances in A-to-I RNA editing have been correlated with human disease phenotypes.

Keywords: ADAR, RNA editing, ALS, DSH, depression, epilepsy, serotonin receptor, glutamate receptor

1. ADAR and A-to-I RNA editing

The complexity of higher organisms is based on the number of different gene products available for structural, enzymatic and regulatory functions. With a rather limited set of genes available in the genomes of even the most highly evolved species, mechanisms controlling gene utilization play a major role in the creation of proteomic and phenotypic diversity. Several post-transcriptional and post-translational mechanisms have been identified that lead to the production of multiple gene products from a single gene. The alternative splicing of pre-mRNAs is a particularly frequent event, estimated to affect more than 70% of mammalian primary transcripts 1,2. Another post-transcriptional processing pathway that appears to be widespread in mammals is A-to-I RNA editing where individual adenosine (A) bases in pre-mRNA are modified to yield inosine (I). A-to-I RNA editing is catalyzed by ADAR (adenosine deaminase acting on RNA) 3-6. Three ADAR gene family members (ADAR1-3) have been identified in vertebrate (Fig. 1A) 7,8. ADAR1 and ADAR2 are detected in many tissues, whereas ADAR3 is expressed specifically in brain. ADAR1 protein is synthesized in two forms as a result of alternative splicing. The ADAR1 mRNA transcribed from an IFN-inducible promoter 9 directs translation of a full-length 150-kDa form of ADAR1 protein (p150). The two other ADAR1 mRNAs, transcribed from constitutive promoters, direct synthesis of a shorter 110-kDa ADAR1 protein (p110) initiated from a downstream Met codon (Fig. 1B). The IFN-inducible p150 protein is detected mainly in the cytoplasm, whereas the constitutively expressed p110 protein is present exclusively in the nucleus 9. A single ADAR2-like gene, dADAR, is present in D. melanogaster 10, whereas two less conserved genes, c.e.ADA1 and c.e.ADA2 exist in C. elegans 11 (Fig. 1A). The sequences of c.e.ADA1 and c.e.ADA2 differ significantly from the three mammalian ADAR genes 11-13. No ADAR gene has been identified in the genomes of plants, fungi and yeast.

Figure 1
Members of the ADAR gene family

Since inosine acts as guanosine during translation, A-to-I conversion in coding sequences leads to amino acid changes and often entails changes in protein function. The power of RNA editing in the generation of protein diversity lies in the fact that usually both the edited and unedited versions of the protein are co-expressed in the same cell and the ratio between the unedited and edited variants can be regulated in a cell type-specific or time-dependent manner. In addition to these cases where the editing occurs in coding regions of gene transcripts, A-to-I editing events have also been detected in noncoding regions of cellular genes 14,15 and within viral RNAs after infection 16-18. In one case, an RNA editing enzyme edits its own pre-mRNA creating a new splice site that leads to alternative splicing 15,19. Recently, thousands of editing sites have been mapped to Alu repeat elements within human pre-mRNAs 20-23, including some examples that could lead to the alteration or creation of splice sites by A-to-I modification 20. The editing events seen in 5′- and 3′- untranslated regions and the intronic sequencesAn external file that holds a picture, illustration, etc.
Object name is nihms-234555-ig0001.jpg might point toward yet unexplored roles of editing in regulating the transport, stability, or further processing of RNAs as well as silencing of retrotransposons.

In mammals, as well as flies and worms, A-to-I RNA editing regulates important functional properties of neurotransmitter receptors in the central nervous system 11-13,24-28. In particularAn external file that holds a picture, illustration, etc.
Object name is nihms-234555-ig0002.jpg the glutamate receptor subunit GluR-2 undergoes almost quantitative editing (>99.9 %) at one position (the Q/R-site), which represents the molecular determinant for low Ca2+-permeability of the ion channel 26. In addition, the Q/R-site regulates the intracellular trafficking and tetramerization of the receptor protein 27,28. Transgenic mice with even slightly reduced GluR-2 editing suffer severe epileptic seizures and die within 2 weeks of age 29. This phenotype was a consequence of the increased Ca2+-permeability of the underedited glutamate receptors 29. The same phenotype resulted when the editing enzyme ADAR2 was inactivated in mice, due to a dramatic reduction in Q/R-site editing 13. Other neuronal genes affected by A-to-I RNA editing include the glutamate receptor subunits GluR-3, -4, -5, and -6 where RNA editing regulates gating and kinetic properties of the ion channels 30,31, the 5-HT2C serotonin receptor subtype where editing is known to regulate G-protein coupling functions of the receptor 32, and the K(V)1.1 potassium channel where editing regulates channel inactivation 33.

Since RNA editing serves to fine-regulate neurotransmission and is involved in the evolution of higher functions, it is naturally anticipated that malfunction of the process would lead to human diseases of learning, memory, language, thinking, and behavior. In the last several years, diseases of the central nervous system, such as depression, epilepsy, schizophrenia and amyotrophic lateral sclerosis (ALS) 34 have indeed been linked to a deregulation of RNA editing. In addition, the genetic linkage map of a human pigmentation disease led to identification of ADAR1 as the responsible gene.

2. Dyschromatosis symmetrica hereditaria

Dyschromatosis symmetrica hereditaria (DSH) is a pigmenting genodermatosis with an autosomal dominant inheritance 11-13. In two independent studies, one based on several affected Japanese families 35 and one using Chinese pedigrees 36, the locus for DSH was recently mapped to the ADAR1 gene on chromosome 1q21.3 through linkage analysis followed by mutational scanning/SNP mapping. An initial set of 11 independent mutations were identified (4 Japanese and 8 Chinese pedigrees) all co-segregating with the DSH phenotype. Since then, 21 additional ADAR1 mutations (heterozygous) were identified in DSH patients 37-44. Figure 2 lists all known mutations with their predicted consequences on ADAR1 expression, which consists of 12 missense, 9 frameshift, 8 nonsense, and 3 splice site (IV2, IV8 and IV12) mutations. Among 32 mutations identified in total, the H216fs mutation (Fig. 2) is specifically interesting, since this frame shift mutation is located upstream of the methionine codon 296, which is used as the initiation codon for translation of the p110 form of ADAR1 45. Thus, no p150 form ADAR1 is synthesized from the mutated allele, but there should be no problem to synthesize p110 proteins in the patients carrying this particular mutation (Fig. 1B). This mutation is clearly linked to the DSH phenotype, indicating that the dosage of functional p150 proteins is a dominant denominator of DSH. It has been recently reported that the p150 form of ADAR1 is involved in antiapoptotic pathways 46. Furthermore, p150 appears to regulate cellular RNAi efficacy by sequestering siRNA 47. It is of special interest to find out whether these ADAR1 functions specific to the p150 isoform, especially its function in the regulation of RNAi, have any causative relevance to DSH pathogenesis.

Figure 2
Mutations of the ADAR1 gene identified in patients with DSH

Regardless of the involvement of p150 or p110, the observed link of ADAR1 gene mutations and DSH raises several questions with regard to the disease mechanism and the role of different ADAR1 mutant proteins. For example, there seems to be no correlation between genotype and phenotype as carriers with the same mutation show distinct clinical manifestations of the disorder indicating the contribution of environmental factors on disease development and progression 36. Furthermore, in some of the Chinese pedigrees the penetrance of the ADAR1 mutation was not 100%. Since in those patients no other ADAR1 mutations were detected it is not clear if in those cases the inherited mutation has a causative role in disease development.

The fact that DSH is inherited in a dominant fashion indicates a gain-of-function disease mechanism or a dominant negative effect of the mutant proteins on normal ADAR1 function. The finding that formation of a homodimer complex is essential for enzymatic activities of mammalian ADAR1 and ADAR2 48 as well as Drosophila dADAR 49 certainly supports the latter possibility. Finally, it is noteworthy that in mice heterozygous for an ADAR1 null mutation no phenotype is discernible 46,50, whereas homozygous ADAR1 knock-out animals die during early embryogenesis 46,50. No pigmentation abnormality is detected with limbs of ADAR1+/− mice (K. Nishikura, unpublished results). It will be interesting to see if an ADAR1-specific RNA editing target(s) will emerge in the future that can explain the observed DSH phenotype and disease mechanism.

3. Amyotrophic lateral sclerosis

ALS is a progressive neurodegenerative disease that affects approximately 1 in 2000 people over their lifetime 51. Usually fatal within 1-5 years after onset, the causes for most cases of ALS (90-95% of all cases with sporadic onset) are unknown. In ALS a specific subset of neurons (motor neurons) degenerates causing the progressive symptoms associated with ALS: muscle weakness, muscle atrophy, spasticity and eventually paralysis and respiratory failure. The unusual asymmetry of motor neurons with axons of up to 1 meter in length makes them particularly vulnerable for disturbances in axonal transport and metabolic defects.

Studies on familial cases of ALS which make up 5-10% of cases have implicated several genes and pathways in the pathology of the disease. In 15-20% of familial ALS mutations in the gene of radical scavenger SOD1 (converts superoxide to water and hydrogen peroxide) are associated with ALS possibly through a gain-of-function mechanism. Deposits of SOD1 and other proteins in motor neurons that are detectable before onset of clinical symptoms are believed to be caused by misfolded SOD1 and proteasome dysfunction due to aggregated, mutant SOD1. Both in sporadic and familial ALS, accumulation of neurofilament proteins in axons of motor neurons is observed, but as for other types of protein deposits associated with several neurodegenerative diseases (such as Alzheimer’s and Parkinson Disease) it is not clear if the deposits are causative for the disease or might serve a protective function.

Glutamate excitotoxicity appears to contribute to the pathology of sporadic ALS: glutamate levels were increased in 40% of sporadic ALS cases, suggesting that prolonged activation of glutamate gated ion channels might lead to excessive Ca2+ influx and neuronal death 52. The cause for the observed increase in synaptic glutamate could be traced to a selective loss in activity of EAAT2 (excitatory amino acid transporter 2), a glutamate transporter located on astrocytes that quickly clears the synaptic cleft of glutamate after excretion 53.

The contribution of excessive Ca2+ influx through glutamate receptors to the death of motor neurons is at the heart of the recent suggestion that RNA editing might play a role in ALS. Editing of the Q/R position in GluR-2 is the molecular determinant for the observed low Ca2+-permeability of AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)-type glutamate receptors in most neurons. A decrease or loss of RNA editing function specifically in motor neurons could lead to AMPA-channels highly permeable to Ca2+, mimicking or exacerbating the overexcitation of glutamate receptors due to EAAT loss. This is exactly what Kwak and colleagues found when they analyzed the RNA editing status of GluR-2 in spinal motor neurons from ALS patients in comparison with normal controls 34,54-56. In the diseased neurons editing of the GluR-2 Q/R position was severely decreased in most samples (ranging from 62-100%) whereas all control cells showed 100% editing 55. The deficiency in RNA editing of the GluR-2 Q/R position is not detected in motor neurons of rats transgenic for mutant human SOD1 (an animal model for families with ALS) or in those of patients with spinal and bulbar muscular atrophy, a non-ALS motor neuron disease 57. These findings indicate that abnormal editing may be a contributory cause of neuronal death specifically in sporadic ALS 56. It is not known when during disease progression this impairment in editing arises or if it might be a causative event during the onset of ALS. Furthermore, the editing deficiency is seen only in spinal motor neurons, whereas upper motor neurons, which also degenerate in ALS, showed unaltered editing levels of GluR-2. This means that a defect in Q/R site editing cannot be the sole mechanism responsible for the demise of the motor neurons. Maybe a mouse model with inducible motor neuron specific RNA editing deficiency will be able to resolve this issue.

Additional evidence for a contribution of Ca2+-permeable AMPA-receptors to motor neuron degeneration comes from a recent genetic mouse model 45. The expression of AMPA-receptors that harbor GluR-2 subunits with the residue N at the Q/R position results in channels with modestly increased Ca2+-permeability (with no substantial effect on overall conductance 58) and the mice develop late-onset motor neuron disease resembling the pathological changes observed in sporadic ALS. As discussed below, substantial increase in Ca2+-permeability of AMPA receptors in principal neurons leads to early lethality precluding the observation of late-onset degenerative disease. Furthermore, in the background of the SOD1 G93A mutation, which has been linked to cases of familial ALS 51, the GluR-2(N) mutation accelerates disease progression and decreases survival 59. Figure 3 illustrates the current knowledge of how RNA editing deficiency specifically in motor neurons might contribute to motor neuron death in ALS.

Figure 3
Contribution of RNA editing deficiency to motor neuron toxicity in ALS

4. Epilepsy

Epilepsy is one of the most common neurological disorders characterized by recurrent, unprovoked seizures [for review see 60]. The causes for epilepsy as well as the symptoms associated with a seizure can be divers and depend on the normal functional roles of the affected neuronal subpopulation. All epileptic phenotypes share the common feature of neuronal hyperexcitability that occasionally leads to seizures.

Due to the central function of AMPA-type glutamate receptors in fast excitatory neurotransmission, they also have been recognized to play a prominent role in the development, expression and spread of seizures. In various instances changes in AMPA receptor subunit expression, channel density or posttranscriptional regulation have been observed in human epilepsy or animal seizure models 61. Generally, CNS injury, such as stroke or traumatic brain injury can lead to secondary neuronal death due to glutamate exitotoxicity, which causes an irreversible elevation in intracellular Ca2+ions. The Ca2+ hypothesis of epileptogenesis proposes that neurons that are exposed to extended but non-lethal levels of elevated Ca2+ undergo plasticity changes that result in acquired epilepsy 60.

Several lines of evidence point towards a connection between changes in glutamate receptor editing and seizure vulnerability. The epileptic phenotypes seen in GluR-2 editing deficient mice 13,29 are most profound and the severity of seizure activity correlates directly with degree of impairment in editing of the Q/R-position 58. The molecular mechanism for epileptogenesis in these transgenic mice has not been elucidated, but it is likely that the changes in AMPA-channel properties due to the expression of GluR-2(Q) are the cause for the observed seizure phenotype. This is suggested by the fact that the phenotype can be rescued by pre-editing GluR-2 messages through genomic mutation 13. The epileptic phenotype of the described editing deficient mouse models could be the result of a neurodevelopmental defect instead of being a direct consequence of altered AMPA-receptor function in the adult brain. This issue was recently addressed in a conditional mouse mutant where GluR-2 editing is inactivated postnatally in selected forebrain regions 62. In support of the notion that unedited GluR-2 directly causes neuron hyperexcitability it was observed that also in adult mice editing deficiency induced seizures with similarity to human temporal lobe epilepsy 62.

A critical remaining question is how changes in GluR-2 Q/R site editing lead to hyperexcitability and epileptic seizures. The results from the various mouse models that alter AMPA receptor function by either downregulating or eliminating GluR-2 expression or by inhibiting GluR-2 editing show that expression of unedited GluR-2(Q) is a necessary requirement for seizure generation. In contrast, elimination of GluR-2 expression, which also results in Ca2+-permeable AMPA receptors, does not precipitate an epileptic phenotype in mice. These differences are likely due to the fact that the nature of the Q/R site residue determines not only the AMPA receptor Ca2+-permeability, but also regulates gating kinetics, channel conductance, and channel assembly, as well as channel trafficking 27,28. Epilepsies associated with human malignant brain tumors (glioblastoma multiforme) [reviewed in 63] might also be linked to a decrease in GluR-2 Q/R site editing 64. RNA editing of the GluR-2 R/G site, as well as the alternative splicing of 5-HT2C receptor pre-mRNA, which is co-regulated by editing, were also altered 64. ADAR2 activity was found to be reduced in tissue specimen from glioblastoma patients compared to white matter controls 64.

An editing deficiency at the Q/R editing site of the kainate-specific glutamate receptor subunit GluR-6 has been linked to seizure vulnerability in mice 65. The deletion of the editing site complementary sequence (ECS) in the mouse GluR-6 gene, which results in a complete loss of editing at the Q/R position, did not give rise to spontaneous seizures, and there was no change in the time to seizure onset after kainate injection, but rather increased seizure vulnerability in GluR-6 ECS knock-out mice. Vulnerability to kainate-induced seizures was inversely correlated with the extent of GluR-6 Q/R-site editing 65. Kainate-induced seizures in mice are a model of temporal lobe epilepsy in humans 66,67. However, analysis of tissue specimen from patients with temporal lobe epilepsy did not show a decrease in editing efficiency at any of the GluR sites 68.

5. Depression and schizophrenia

No specific gene has been definitively identified for any major psychiatric disorder, including major depression and schizophrenia 69. While this might in part be due to poor study design and the complexity of mental disorders, epigenetic factors that modify gene expression have been indicated as another potentially important issue. Because epigenetic modifications are essential mechanisms for most genes to adapt functionality in response to a variable environment, an inadequate epigenetic modification of the genes could be a causative mechanism for inducing mental disorders.

Members of the serotonin (5-hydroxytryptamine or 5-HT) receptor gene family are believed to play important roles in physiological and behavioral processes such as circadian rhythms, emotion, appetite and sexual behavior. Furthermore, 5-HT receptors may have a causative relevance to human mental abnormalities and pathology, including major depression, schizophrenia, anxiety, migraine, and substance dependency 70. Among at least 14 distinct subtypes of 5-HT receptors (5-HTRs) expressed within the central nervous system 71, the 5-HT2CR is the only known G-protein coupled receptor whose mRNA undergoes post-transcriptional editing, a major epigenetic mechanism, to yield different receptor isoforms in humans and rodents 72.

Editing in the 5-HT2CR pre-mRNA takes place at five positions in exon 5 (Fig. 4A). The receptor function is modulated by RNA editing through three distinct mechanisms. First, editing of five sites (A-E sites) situated within the second intracellular loop region changes the genomically-encoded amino acids Ile, Asp, and Ile at positions 156, 158, and 160, respectively, resulting in alteration of G protein-coupling efficacy (Fig. 4B). The fully edited isoform (5-HT2CR-VGV) profoundly reduces 5-HT potency, G-protein coupling and agonist binding, compared to the unedited protein isoform (5-HT2CR-INI) (Fig. 4B) 72-76. Second, the editing pattern controls the amount of the 5-HT2CR mRNA that leads to the expression of full-length protein through the modulation of alternative splice site selection 76,77. Among three alternative splice donor sites (GU1 to GU3; Fig. 4C), GU2 is the only site that forms the mature mRNA to produce the functional, full-length 5-HT2CR protein. Unedited pre-mRNAs tend to be spliced at the GU1 site, resulting in the truncated, non-functional protein if translated 76,77. However, most pre-mRNAs edited at more than one position are spliced at GU2 77. Thus, when editing is inefficient, increased splicing at GU1 may act as a control mechanism to decrease biosynthesis of the 5-HT2CR-INI and thereby limit serotonin response. Third, RNA editing controls the ultimate physiological output of constitutively active receptors by affecting the cell surface expression of the 5-HT2CR. The 5-HT2CR-VGV, which displays the lowest level of constitutive activity, is fully expressed at the cell surface under basal conditions and is rapidly internalized in the presence of agonist 78. In contrast, the 5-HT2CR-INI is constitutively internalized and accumulates in endosomes 78.

Figure 4
RNA editing of 5-HT2CR by ADARs can generate various protein isoforms with altered functions

Associations between major psychiatric disorders and the pattern of RNA editing at 5 editing sites of the 5-HT2CR have been investigated in recent years (Table 1). No alteration of the editing pattern was found in three independent studies conducted regarding schizophrenia 79-81. One group claimed that the expression level of the 5-HT2CR-INI was significantly increased 82, however, this discrepancy could be due to small sample size, different methodologies, and the medication history of investigated subjects. On the other hand, multiple groups reported an increased RNA editing efficiency at the A site in brains of depressed suicide victims 80,81. Moreover, Gurevich et al. reported that E site editing is significantly increased as well in individuals with major depression 83. This alteration is also observed in a rat model of depression and can be reverted through treatment with the serotonin-selective reuptake blocker fluoxetine 84. In addition, mice chronically treated with fluoxetine also exhibit decreased E site editing 85, suggesting that E site editing might be associated with the pathophysiological status of major depression.

Table 1
The pattern of 5-HT2CR editing in subjects with psychiatric disorders

It has been revealed that the pattern of 5-HT2CR editing is significantly different among inbred strains of mice 86. In C57BL/6 and 129SV, more than 80% of forebrain neocortical 5-HT2CR mRNAs are edited at A, B, and D sites or A, B, C, and D sites. C57BL/6 mice show no alteration of the editing pattern against acute stress or chronic treatment of fluoxetine. In contrast, in the BALB/c strain, about 80% of 5-HT2CR mRNAs are not edited at all and encode receptors with the highest constitutive activity and the highest agonist affinity and potency. However, exposure of BALB/c mice to acute stress or chronic treatment with fluoxetine elicit significant increases of RNA editing at sites A to D 86. Interestingly, BALB/c mice have a deficiency in the 5-HT biosynthesis pathway and thus, may need to maintain a high level of unedited 5-HT2CR mRNAs to compensate for their naturally low concentration of 5-HT. These observations imply that editing responsiveness to stress and medication is modulated by genetic background, as well as behavioral state, suggesting that association studies using postmortem brains have limitations and that the development of animal models, such as 5-HT2CR editing-deficient mice, will be needed to gain substantial insights into the relationships between RNA editing of 5-HTRs and mental disorders.

6. Involvement of ADARs in hypermutation and persistent infection of measles virus

A-to-I RNA editing seems to be responsible for several reported cases of biased hypermutation affecting RNA viruses during persistent infections in humans that lead to severe neurological disease 18. In the matrix gene of a defective measles virus, isolated from the brain tissue of a measles inclusion body encephalitis (MIBE) patient, 50% of the A residues (132 of 266A) of the minus-strand RNA genome were found to be mutated to G after cDNA cloning and sequencing of the viral RNAs. These mutations in the viral RNAs appear to have been introduced by ADARs 18,87. The extensive sequence changes drastically altered the coding capacity of the matrix gene including the elimination of a translation initiation codon, which resulted in suppression of translation of its mRNA 18. The lack of matrix gene expression may help the virus to escape immune system recognition and thus, allow persistent infection 18. Two more examples of highly biased A to G mutations have been found in the hemagglutinin gene of another strain of measles virus isolated from a patient with subacute sclerosing panencephalitis (SSPE) 18. It has been speculated that biased hypermutation mediated by ADARs takes place in vivo as frequently in lytic as in persistent infections, but are propagated only in the genome of persistent viruses or defective-interfering particles because of the lower selective pressures operating in these infections. The frequency and extent of biased hypermutation events seen in persistant infections of the brain might also be a function of the high expression levels of ADAR1 and ADAR2 in brain 87.

7. Outlook

Changes in A-to-I RNA editing have now been linked to various human disorders and the increased understanding of the editing mechanism and target spectrum can explain some of the phenotypic features that result from RNA editing deficiency or hyperactivity. In general, a disease-related alteration of editing could manifest itself on several levels. If it is the editing substrate that becomes altered or misregulated the change in editing levels will be gene-specific and represent a secondary event in disease development. As a result, the editing efficiency and/or site-selectivity for this single substrate may be altered in all tissues where it is expressed. On the other hand, the aberration in RNA editing can be cell-type specific through deregulation of the editing machinery. Thereby, it may affect many transcripts within a single tissue or cell-type. The specific editing deficiency observed in motor-neurons of sporadic ALS patients 34,54-56 is an example for such a scenario as well as the hyperediting phenotype seen within immune cells during inflammation 88. Lastly, the editing hyper- or hypoactivity of an ADAR enzyme may be global, thereby affecting many different RNAs with diverse consequences.

In the future, animal models that mimic individual situations will be the most appropriate means of studying the causal relationships between RNA editing malfunction and disease phenotypes. It is crucial to understand how A-to-I editing is regulated in vivo – a topic that is only beginning to be investigated. Important observations regarding this aspect are that ADARs are expressed from alternative promoters and undergo various alternative splicing events 89-91, the activity of ADAR enzymes is modulated by post translational modification 92, regulation of subcellular localization of ADARs 93-96, and a small molecule (inositol hexakisphosphate, IP6) was recently recognized as an essential co-factor for ADAR catalytic function 97. ADAR activity is also affected by the action of small nucleolar RNAs (ADAR2) 98 and through alternative dsRNA substrate conformation (ADAR1) 99.

What makes studying these interrelationships more difficult and at the same time more interesting is the realization that RNA editing is closely linked to other RNA processing events as well as regulatory mechanisms mediated by RNA molecules. It has been recently reported that miRNA precursors are also subject to A-to-I RNA editing 100-102, and the miRNA biogenesis pathway and the expression levels of mature miRNAs are regulated by A-to-I RNA editing 100. Interestingly, the cytoplasmic, full-length isoform of ADAR1p150 sequesters siRNA and suppresses the potency of siRNA 47. Tudor-SN, a component of RISC (RNA-induced silencing complex), cleaves specifically highly edited dsRNAs with continuous I·U and U·I base pairs 103,104. Finally, the chemotaxis defective phenotype of C. elegans strains containing homozygous deletions of c.e.ADA1 and c.e.ADA2 revealed that their phenotype can be reverted through inactivation of the RNAi pathway 105. These recent findings all indicate frequent interactions between A-to-I editing and RNA silencing pathways and a potential role for ADARs in the regulation of RNAi. It should be pointed out that malfunctioning of the editing mechanism and consequent deficiencies in editing of protein coding and non-coding RNAs as well as insufficiency in the interaction between the RNAi and editing pathways may give rise to human diseases and pathophysiology much more complicated than those caused by mutation of a single protein coding gene.


serotonin receptor subunit 2C
adenosine deaminase acting on RNA
amyotrophic lateral sclerosis
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
dyschromatosis symmetrica hereditaria
excitatory amino acid transporter 2
glutamate receptor
RNA-induced silencing complex
superoxide dismutase 1


1. Kampa D, et al. Novel RNAs identified from an in-depth analysis of the transcriptome of human chromosomes 21 and 22. Genome Res. 2004;14:331–42. [PubMed]
2. Johnson JM, et al. Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science. 2003;302:2141–4. [PubMed]
3. Bass BL. RNA editing by adenosine deaminases that act on RNA. Annu Rev Biochem. 2002;71:817–46. [PMC free article] [PubMed]
4. Keegan LP, Gallo A, O’Connell MA. The many roles of an RNA editor. Nat Rev Genet. 2001;2:869–78. [PubMed]
5. Gott JM, Emeson RB. Functions and mechanisms of RNA editing. Annu Rev Genet. 2000;34:499–531. [PubMed]
6. Maas S, Rich A, Nishikura K. A-to-I RNA editing: recent news and residual mysteries. J Biol Chem. 2003;278:1391–4. [PubMed]
7. Slavov D, Crnogorac-Jurcevic T, Clark M, Gardiner K. Comparative analysis of the DRADA A-to-I RNA editing gene from mammals, pufferfish and zebrafish. Gene. 2000;250:53–60. [PubMed]
8. Slavov D, Clark M, Gardiner K. Comparative analysis of the RED1 and RED2 A-to-I RNA editing genes from mammals, pufferfish and zebrafish. Gene. 2000;250:41–51. [PubMed]
9. Patterson JB, Samuel CE. Expression and regulation by interferon of a double-stranded-RNA-specific adenosine deaminase from human cells: evidence for two forms of the deaminase. Mol Cell Biol. 1995;15:5376–88. [PMC free article] [PubMed]
10. Palladino MJ, Keegan LP, O’Connell MA, Reenan RA. dADAR, a Drosophila double-stranded RNA-specific adenosine deaminase is highly developmentally regulated and is itself a target for RNA editing. Rna. 2000;6:1004–18. [PubMed]
11. Tonkin LA, et al. RNA editing by ADARs is important for normal behavior in Caenorhabditis elegans. Embo J. 2002;21:6025–35. [PubMed]
12. Palladino MJ, Keegan LP, O’Connell MA, Reenan RA. A-to-I pre-mRNA editing in Drosophila is primarily involved in adult nervous system function and integrity. Cell. 2000;102:437–49. [PubMed]
13. Higuchi M, et al. Point mutation in an AMPA receptor gene rescues lethality in mice deficient in the RNA-editing enzyme ADAR2. Nature. 2000;406:78–81. [PubMed]
14. Morse DP, Aruscavage PJ, Bass BL. RNA hairpins in noncoding regions of human brain and Caenorhabditis elegans mRNA are edited by adenosine deaminases that act on RNA. Proc Natl Acad Sci U S A. 2002;99:7906–11. [PubMed]
15. Rueter SM, Dawson TR, Emeson RB. Regulation of alternative splicing by RNA editing. Nature. 1999;399:75–80. [PubMed]
16. Bass BL. RNA editing and hypermutation by adenosine deamination. Trends Biochem Sci. 1997;22:157–62. [PubMed]
17. Polson AG, Bass BL, Casey JL. RNA editing of hepatitis delta virus antigenome by dsRNA-adenosine deaminase. Nature. 1996;380:454–6. [PubMed]
18. Cattaneo R, et al. Biased hypermutation and other genetic changes in defective measles viruses in human brain infections. Cell. 1988;55:255–65. [PubMed]
19. Dawson TR, Sansam CL, Emeson RB. Structure and sequence determinants required for the RNA editing of ADAR2 substrates. J Biol Chem. 2004;279:4941–51. [PubMed]
20. Athanasiadis A, Rich A, Maas S. Widespread A-to-I RNA editing of Alu-containing mRNAs in the human transcriptome. PLoS Biol. 2004;2:e391. [PMC free article] [PubMed]
21. Kim DD, et al. Widespread RNA editing of embedded alu elements in the human transcriptome. Genome Res. 2004;14:1719–25. [PubMed]
22. Levanon EY, et al. Systematic identification of abundant A-to-I editing sites in the human transcriptome. Nat Biotechnol. 2004;22:1001–5. [PubMed]
23. Blow M, Futreal PA, Wooster R, Stratton MR. A survey of RNA editing in human brain. Genome Res. 2004;14:2379–87. [PubMed]
24. Seeburg PH, Hartner J. Regulation of ion channel/neurotransmitter receptor function by RNA editing. Curr Opin Neurobiol. 2003;13:279–83. [PubMed]
25. Schmauss C, Howe JR. RNA editing of neurotransmitter receptors in the mammalian brain. Sci STKE. 2002;2002:PE26. [PubMed]
26. Seeburg PH, Higuchi M, Sprengel R. RNA editing of brain glutamate receptor channels: mechanism and physiology. Brain Res Brain Res Rev. 1998;26:217–29. [PubMed]
27. Greger IH, Khatri L, Kong X, Ziff EB. AMPA receptor tetramerization is mediated by Q/R editing. Neuron. 2003;40:763–74. [PubMed]
28. Greger IH, Khatri L, Ziff EB. RNA editing at arg607 controls AMPA receptor exit from the endoplasmic reticulum. Neuron. 2002;34:759–72. [PubMed]
29. Brusa R, et al. Early-onset epilepsy and postnatal lethality associated with an editing-deficient GluR-B allele in mice. Science. 1995;270:1677–80. [PubMed]
30. Kohler M, Burnashev N, Sakmann B, Seeburg PH. Determinants of Ca2+ permeability in both TM1 and TM2 of high affinity kainate receptor channels: diversity by RNA editing. Neuron. 1993;10:491–500. [PubMed]
31. Lomeli H, et al. Control of kinetic properties of AMPA receptor channels by nuclear RNA editing. Science. 1994;266:1709–13. [PubMed]
32. Burns CM, et al. Regulation of serotonin-2C receptor G-protein coupling by RNA editing. Nature. 1997;387:303–8. [see comments] [PubMed]
33. Bhalla T, Rosenthal JJ, Holmgren M, Reenan R. Control of human potassium channel inactivation by editing of a small mRNA hairpin. Nat Struct Mol Biol. 2004;11:950–6. [PubMed]
34. Kwak S, Kawahara Y. Deficient RNA editing of GluR2 and neuronal death in amyotropic lateral sclerosis. J Mol Med. 2005;83:110–20. [PubMed]
35. Miyamura Y, et al. Mutations of the RNA-specific adenosine deaminase gene (DSRAD) are involved in dyschromatosis symmetrica hereditaria. Am J Hum Genet. 2003;73:693–9. [PubMed]
36. Zhang XJ, et al. Seven novel mutations of the ADAR gene in Chinese families and sporadic patients with dyschromatosis symmetrica hereditaria (DSH) Hum Mutat. 2004;23:629–30. [PubMed]
37. Cui Y, et al. Identification of a novel mutation in the DSRAD gene in a Chinese pedigree with dyschromatosis symmetrica hereditaria. Arch Dermatol Res. 2005;296:543–5. [PubMed]
38. Gao M, et al. Two frameshift mutations in the RNA-specific adenosine deaminase gene associated with dyschromatosis symmetrica hereditaria. Arch Dermatol. 2005;141:193–6. [PubMed]
39. Li CR, et al. A new arginine substitution mutation of DSRAD gene in a Chinese family with dyschromatosis symmetrica hereditaria. J Dermatol Sci. 2005;37:95–9. [PubMed]
40. Li M, et al. A novel mutation of the DSRAD gene in a Chinese family with dyschromatosis symmetrica hereditaria. Clin Exp Dermatol. 2004;29:533–5. [PubMed]
41. Liu Q, et al. Novel mutations of the RNA-specific adenosine deaminase gene (DSRAD) in Chinese families with dyschromatosis symmetrica hereditaria. J Invest Dermatol. 2004;122:896–9. [PubMed]
42. Suzuki N, et al. Mutation analysis of the ADAR1 gene in dyschromatosis symmetrica hereditaria and genetic differentiation from both dyschromatosis universalis hereditaria and acropigmentatio reticularis. J Invest Dermatol. 2005;124:1186–92. [PubMed]
43. Sun XK, Xu AE, Chen JF, Tang X. The double-RNA-specific adenosine deaminase (DSRAD) gene in dyschromatosis symmetrica hereditaria patients: two novel mutations and one previously described. Br J Dermatol. 2005;153:342–5. [PubMed]
44. Xing Q, et al. Identification of a novel ADAR mutation in a Chinese family with dyschromatosis symmetrica hereditaria (DSH) Arch Dermatol Res. 2005:1–4. [PubMed]
45. Kuner R, et al. Late-onset motoneuron disease caused by a functionally modified AMPA receptor subunit. Proc Natl Acad Sci U S A. 2005;102:5826–31. [PubMed]
46. Wang Q, et al. Stress-induced apoptosis associated with Null mutation of ADAR1 RNA editing deaminase gene. J Biol Chem. 2003 [PubMed]
47. Yang W, et al. ADAR1 RNA deaminase limits short interfering RNA efficacy in mammalian cells. J Biol Chem. 2005;280:3946–53. [PMC free article] [PubMed]
48. Cho DS, et al. Requirement of dimerization for RNA editing activity of adenosine deaminases acting on RNA. J Biol Chem. 2003;278:17093–102. [PubMed]
49. Gallo A, Keegan LP, Ring GM, O’Connell MA. An ADAR that edits transcripts encoding ion channel subunits functions as a dimer. Embo J. 2003;22:3421–30. [PubMed]
50. Hartner JC, et al. Liver disintegration in the mouse embryo by deficiency in RNA editing enzyme ADAR1. J Biol Chem. 2003 [PubMed]
51. Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci. 2001;2:806–19. [PubMed]
52. Spreux-Varoquaux O, et al. Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients. J Neurol Sci. 2002;193:73–8. [PubMed]
53. Rothstein JD, Van Kammen M, Levey AI, Martin LJ, Kuncl RW. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol. 1995;38:73–84. [PubMed]
54. Kawahara Y, et al. Human spinal motoneurons express low relative abundance of GluR2 mRNA: an implication for excitotoxicity in ALS. J Neurochem. 2003;85:680–9. [PubMed]
55. Kawahara Y, et al. Glutamate receptors: RNA editing and death of motor neurons. Nature. 2004;427:801. [PubMed]
56. Kawahara Y, Kwak S. Excitotoxicity and ALS: What is unique about the AMPA receptors expressed on spinal motor neurons? Amyotroph Lateral Scler Other Motor Neuron Disord. 2005;6:131–44. [PubMed]
57. Kawahara Y, et al. Underediting of GluR2 mRNA, a neuronal death inducing molecular change in sporadic ALS, does not occur in motor neurons in ALS1 or SBMA. Neuroscience Research. 2005 in press. [PubMed]
58. Feldmeyer D, et al. Neurological dysfunctions in mice expressing different levels of the Q/R site-unedited AMPAR subunit GluR-B. Nat Neurosci. 1999;2:57–64. [PubMed]
59. Kuner R, et al. Mechanisms of disease: motoneuron disease aggravated by transgenic expression of a functionally modified AMPA receptor subunit. Ann N Y Acad Sci. 2005;1053:269–86. [PubMed]
60. Delorenzo RJ, Sun DA, Deshpande LS. Cellular mechanisms underlying acquired epilepsy: the calcium hypothesis of the induction and maintainance of epilepsy. Pharmacol Ther. 2005;105:229–66. [PMC free article] [PubMed]
61. Palmer CL, Cotton L, Henley JM. The molecular pharmacology and cell biology of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. Pharmacol Rev. 2005;57:253–77. [PMC free article] [PubMed]
62. Krestel HE, et al. A genetic switch for epilepsy in adult mice. J Neurosci. 2004;24:10568–78. [PubMed]
63. Beaumont A, Whittle IR. The pathogenesis of tumour associated epilepsy. Acta Neurochir. 2000;142:1–15. [PubMed]
64. Maas S, Patt S, Schrey M, Rich A. Underediting of glutamate receptor GluR-B mRNA in malignant gliomas. Proc Natl Acad Sci U S A. 2001;98:14687–92. [PubMed]
65. Vissel B, et al. The role of RNA editing of kainate receptors in synaptic plasticity and seizures. Neuron. 2001;29:217–27. [PubMed]
66. Nadler JV. Minireview. Kainic acid as a tool for the study of temporal lobe epilepsy. Life Sci. 1981;29:2031–42. [PubMed]
67. Ben-Ari Y. Limbic seizure and brain damage produced by kainic acid: mechanisms and relevance to human temporal lobe epilepsy. Neuroscience. 1985;14:375–403. [PubMed]
68. Kortenbruck G, Berger E, Speckmann EJ, Musshoff U. RNA editing at the Q/R site for the glutamate receptor subunits GLUR2, GLUR5, and GLUR6 in hippocampus and temporal cortex from epileptic patients. Neurobiol Dis. 2001;8:459–68. [PubMed]
69. Abdolmaleky HM, Thiagalingam S, Wilcox M. Genetics and epigenetics in major psychiatric disorders: dilemmas, achievements, applications, and future scope. Am J Pharmacogenomics. 2005;5:149–60. [PubMed]
70. Baxter G, Kennett G, Blaney F, Blackburn T. 5-HT2 receptor subtypes: a family re-united? Trends Pharmacol Sci. 1995;16:105–10. [PubMed]
71. Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology. 1999;38:1083–152. [PubMed]
72. Burns CM, et al. Regulation of serotonin-2C receptor G-protein coupling by RNA editing. Nature. 1997;387:303–8. [PubMed]
73. Herrick-Davis K, Grinde E, Niswender CM. Serotonin 5-HT2C receptor RNA editing alters receptor basal activity: implications for serotonergic signal transduction. J Neurochem. 1999;73:1711–7. [PubMed]
74. Niswender CM, Copeland SC, Herrick-Davis K, Emeson RB, Sanders-Bush E. RNA editing of the human serotonin 5-hydroxytryptamine 2C receptor silences constitutive activity. J Biol Chem. 1999;274:9472–8. [PubMed]
75. Price RD, Weiner DM, Chang MS, Sanders-Bush E. RNA editing of the human serotonin 5-HT2C receptor alters receptor-mediated activation of G13 protein. J Biol Chem. 2001;276:44663–8. [PubMed]
76. Wang Q, et al. Altered G protein-coupling functions of RNA editing isoform and splicing variant serotonin2C receptors. J Neurochem. 2000;74:1290–300. [PubMed]
77. Flomen R, Knight J, Sham P, Kerwin R, Makoff A. Evidence that RNA editing modulates splice site selection in the 5-HT2C receptor gene. Nucleic Acids Res. 2004;32:2113–22. [PMC free article] [PubMed]
78. Marion S, Weiner DM, Caron MG. RNA editing induces variation in desensitization and trafficking of 5-hydroxytryptamine 2c receptor isoforms. J Biol Chem. 2004;279:2945–54. [PubMed]
79. Dracheva S, et al. RNA editing and alternative splicing of human serotonin 2C receptor in schizophrenia. J Neurochem. 2003;87:1402–12. [PubMed]
80. Niswender CM, et al. RNA editing of the human serotonin 5-HT2C receptor. alterations in suicide and implications for serotonergic pharmacotherapy. Neuropsychopharmacology. 2001;24:478–91. [PubMed]
81. Iwamoto K, Kato T. RNA editing of serotonin 2C receptor in human postmortem brains of major mental disorders. Neurosci Lett. 2003;346:169–72. [PubMed]
82. Sodhi MS, Burnet PW, Makoff AJ, Kerwin RW, Harrison PJ. RNA editing of the 5-HT(2C) receptor is reduced in schizophrenia. Mol Psychiatry. 2001;6:373–9. [PubMed]
83. Gurevich I, et al. Altered editing of serotonin 2C receptor pre-mRNA in the prefrontal cortex of depressed suicide victims. Neuron. 2002;34:349–56. [PubMed]
84. Iwamoto K, Nakatani N, Bundo M, Yoshikawa T, Kato T. Altered RNA editing of serotonin 2C receptor in a rat model of depression. Neurosci Res. 2005;53:69–76. [PubMed]
85. Gurevich I, Englander MT, Adlersberg M, Siegal NB, Schmauss C. Modulation of serotonin 2C receptor editing by sustained changes in serotonergic neurotransmission. J Neurosci. 2002;22:10529–32. [PubMed]
86. Englander MT, Dulawa SC, Bhansali P, Schmauss C. How stress and fluoxetine modulate serotonin 2C receptor pre-mRNA editing. J Neurosci. 2005;25:648–51. [PubMed]
87. Bass BL, Weintraub H, Cattaneo R, Billeter MA. Biased hypermutation of viral RNA genomes could be due to unwinding/modification of double-stranded RNA. Cell. 1989;56:331. [PubMed]
88. Yang JH, et al. Widespread inosine-containing mRNA in lymphocytes regulated by ADAR1 in response to inflammation. Immunology. 2003;109:15–23. [PubMed]
89. Kawakubo K, Samuel CE. Human RNA-specific adenosine deaminase (ADAR1) gene specifies transcripts that initiate from a constitutively active alternative promoter. Gene. 2000;258:165–72. [PubMed]
90. George CX, Samuel CE. Human RNA-specific adenosine deaminase ADAR1 transcripts possess alternative exon 1 structures that initiate from different promoters, one constitutively active and the other interferon inducible. Proc Natl Acad Sci U S A. 1999;96:4621–6. [PubMed]
91. Valente L, Nishikura K. ADAR gene family and A-to-I RNA editing: diverse roles in posttranscriptional gene regulation. Prog Nucleic Acid Res Mol Biol. 2005;79:299–338. [PubMed]
92. Desterro JM, et al. SUMO-1 modification alters ADAR1 editing activity. Mol Biol Cell. 2005;16:5115–26. [PMC free article] [PubMed]
93. Desterro JM, et al. Dynamic association of RNA-editing enzymes with the nucleolus. J Cell Sci. 2003;116:1805–18. [PubMed]
94. Sansam CL, Wells KS, Emeson RB. Modulation of RNA editing by functional nucleolar sequestration of ADAR2. Proc Natl Acad Sci U S A. 2003;100:14018–23. [PubMed]
95. Poulsen H, Nilsson J, Damgaard CK, Egebjerg J, Kjems J. CRM1 mediates the export of ADAR1 through a nuclear export signal within the Z-DNA binding domain. Mol Cell Biol. 2001;21:7862–71. [PMC free article] [PubMed]
96. Eckmann CR, Neunteufl A, Pfaffstetter L, Jantsch MF. The human but not the Xenopus RNA-editing enzyme ADAR1 has an atypical nuclear localization signal and displays the characteristics of a shuttling protein. Mol Biol Cell. 2001;12:1911–24. [PMC free article] [PubMed]
97. Macbeth MR, et al. Inositol hexakisphosphate is bound in the ADAR2 core and required for RNA editing. Science. 2005;309:1534–9. [PMC free article] [PubMed]
98. Vitali P, et al. ADAR2-mediated editing of RNA substrates in the nucleolus is inhibited by C/D small nucleolar RNAs. J Cell Biol. 2005;169:745–53. [PMC free article] [PubMed]
99. Koeris M, Funke L, Shrestha J, Rich A, Maas S. Modulation of ADAR1 editing activity by Z-RNA in vitro. Nucleic Acids Res. 2005;33:5362–70. [PMC free article] [PubMed]
100. Yang W, et al. Modulation of microRNA processing and expression through RNA editing by ADAR deaminases. Nat Struct Mol Biol. 2005 in press. [PMC free article] [PubMed]
101. Luciano DJ, Mirsky H, Vendetti NJ, Maas S. RNA editing of a miRNA precursor. Rna. 2004;10:1174–7. [PubMed]
102. Pfeffer S, et al. Identification of microRNAs of the herpesvirus family. Nat Methods. 2005;2:269–76. [PubMed]
103. Scadden AD, O’Connell MA. Cleavage of dsRNAs hyper-edited by ADARs occurs at preferred editing sites. Nucleic Acids Res. 2005;33:5954–64. [PMC free article] [PubMed]
104. Scadden AD. The RISC subunit Tudor-SN binds to hyper-edited double-stranded RNA and promotes its cleavage. Nat Struct Mol Biol. 2005;12:489–96. [PubMed]
105. Tonkin LA, Bass BL. Mutations in RNAi rescue aberrant chemotaxis of ADAR mutants. Science. 2003;302:1725. [PMC free article] [PubMed]